Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Targeted Quantitative Proteomics and Metabolic Labelling With Stable Isotopes for the Diagnosis and the Investigation of Neurological Disorders and in Particular Alzheimer Disease

NCT02263235 is registered in ClinicalTrials.gov with University Hospital, Montpellier as lead sponsor.

NCT NCT02263235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02263235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Targeted Quantitative Proteomics and Metabolic Labelling With Stable Isotopes for the Diagnosis and the Investigation of Neurological Disorders and in Particular Alzheimer Disease
Lead sponsor
University Hospital, Montpellier
Phase
Not applicable
Overall status
Terminated
Start date
October 8, 2013
Completion date
May 22, 2018
Enrollment
89 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute hydrocephaly, brain trauma, neurological disease without cognitive degradation, parkinson disease, probable alzheimer disease